Effect of vericiguat on treatment of elderly patients with heart failure after acute myocardial infarction
Wang Jianming
Long Jingning
Fan Zhenping
Niu Yifang
Liu Hui
Abstract：Objective To explore the clinical efficacy of vericiguat in treatment of elderly patients with heart failure after acute myocardial infarction(AMI)and observe the impact on cardiac function.Methods A total of 96 elderly patients with heart failure after AMI who were admitted to The First Affiliated Hospital of Xinxiang Medical University from August 2022 to July 2024 were randomly divided into two groups,with 48 in each group.The observation group received vericiguat in addition to conventional western medicine,which was solely administered to the control group.The clinical efficacy,cardiac function,myocardial injury indexes and adverse reactions were compared between the two groups before the treatment and after the treatment for 4 weeks.Results The total effective rate of the observation group was 97.92%,higher than 75.00%of the control group(χ2=10.736,P<0.05).The LVEDD and LVESD of the control group and the observation group were respectively(51.39±6.28)mm,(36.02±3.02)mm,(45.12±3.94)mm and(31.08±1.14)mm after the treatment for 4 weeks,lower than(59.35±8.42)mm,(46.39±5.21)mm,(59.02±9.26)mm and(46.28±5.32)mm before the treatment;the levels of LVEF of the two groups were(45.89±3.25)%and(56.25±4.36)%after the treatment for 4 weeks,higher than(36.22±2.87)%and(37.12±2.81)%before the treatment.The above indexes were better in the observation group than in the control group(t=7.504,11.719,25.663,60.258,19.455,33.074,5.859,10.603,13.199,all P<0.05).The MMP-9,MPO and NT-proBNP of the two groups were respectively(98.05±8.95)μg·L-1,(511.25±20.59)μg·L-1,(4 321.05±103.69)pg·mL-1,(56.18±6.14)μg·L-1,(437.06±16.87)μg·L-1 and(2 156.01±98.02)pg·mL-1 after the treatment,lower than(136.88±12.32)μg·L-1,(586.29±24.98)μg·L-1,(8 369.32±167.38)pg·mL-1,(135.72±13.69)μg·L-1,(584.96±25.12)μg·L-1 and(8 371.68±166.58)pg·mL-1 before the treatment;the above indexes of the observation group were lower than those of the control group(t=15.301,22.689,17.305,27.024,46.521,73.021,26.727,19.310,105.124,all P<0.05).There was no significant difference in the incidence of adverse drug reactions between the two groups(4.17%vs 2.08%)(χ2=0.344,P>0.05).Conclusion Vericiguat has good clinical efficacy in treatment of the elderly patients with heart failure after AMI,can effectively improve cardiac function and reduce myocar-dial injury,and does not increase adverse drug reactions,with high safety.
Keywords：VericiguatAcute myocardial infarctionHeart failureClinical efficacyCardiac function
Publication Date：2025-06-25
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 407-410 )